Atara Biotherapeutics, Inc. (ATRA)
| Market Cap | 39.83M |
| Revenue (ttm) | 120.77M |
| Net Income (ttm) | 32.69M |
| Shares Out | 8.18M |
| EPS (ttm) | 2.57 |
| PE Ratio | 1.89 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,751 |
| Open | 4.960 |
| Previous Close | 4.990 |
| Day's Range | 4.780 - 4.970 |
| 52-Week Range | 3.920 - 19.145 |
| Beta | -0.33 |
| Analysts | Sell |
| Price Target | 5.00 (+2.67%) |
| Earnings Date | May 14, 2026 |
About ATRA
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. T... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ATRA stock is "Sell." The 12-month stock price target is $5.0, which is an increase of 2.67% from the latest price.
News
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
NEW YORK, April 28, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of ATRA during ...
ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO, April 16, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NAS...
ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investment, contact Lauren Molinaro of Kirby McIne...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Provides a Business Update
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Tabelecleucel BLA currently under U.S. Food and Drug Administration (FDA) Priority Review as potentially the first approved therapy in the U.S. for EBV+ PTLD with a Prescription Drug User Fee Act (PDU...
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.
Atara Biotherapeutics Announces Changes to Its Board of Directors
THOUSAND OAKS, Calif--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop...
Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
First allogeneic T-Cell therapy BLA offers hope to EBV+ PTLD patients who have limited treatment options and lifespan measured in only a few weeks to months following failure of initial treatment EBV+...
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
Pierre Fabre Laboratories is now responsible for all global clinical trial activities for the tabelecleucel clinical program Enrollment is ongoing for pivotal, Phase 3 ALLELE Study (NCT03394365) inves...
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Transcript: AGM 2025
The meeting covered director elections, executive compensation, auditor ratification, and voting procedures. All proposals passed, with annual advisory votes on compensation chosen. No questions were raised, and final results will be filed with the SEC.
Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Announces Pricing of $16 Million Offering
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develo...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl...
The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / March 1, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biothe...
The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 15, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Bi...
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK , Feb. 14, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights...